[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myeloid-leukemia-aml-in-remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myeloid-leukemia-aml-in-remission":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,104,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633010","abc-maintenance-therapy-for-aml-100633010",false,"NCT07521124","ABC Maintenance Therapy for AML","Efficacy and Safety of Maintenance Treatment With Chidamide, Venetoclax, and Azacitidine for Treatment-Naive Acute Myeloid Leukemia Patients Achieving Complete Remission: A Multicenter Study","ABC-Maint","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years with newly diagnosed Acute Myeloid Leukemia (AML)\n2. Patients who have achieved their first Complete Remission (CR) or Complete Remission with incomplete hematologic recovery (CRi) at the time of enrollment, following induction therapy with intensive chemotherapy and at least 2 cycles of consolidation therapy. Remission must have been achieved within 4 months (±7 days) prior to enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n4. Women of childbearing potential are eligible if they meet the following conditions:\n\n   1. A negative serum or urine pregnancy test is performed within 10-14 days prior to enrollment, and a second negative pregnancy test is performed within 24 hours prior to the initiation of treatment. Both negative results are required to meet the criteria for treatment initiation.\n   2. They agree to practice abstinence or use two effective methods of contraception during the treatment period and for 28 days after discontinuation of the study drug.\n5. Male patients with female partners of childbearing potential are eligible if they agree to practice abstinence or use two effective methods of contraception during the treatment period and for 28 days after discontinuation of the study drug.\n6. Women of childbearing potential must comply with scheduled pregnancy tests.\n7. Ability to understand and sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n1. Diagnosis of Acute Promyelocytic Leukemia (APL) or FAB subtype M3 AML.\n2. Patients with a history of extramedullary leukemia, unless central nervous system (CNS) involvement is controlled.\n3. Laboratory values that do not meet the following criteria: Total Bilirubin ≤ 1.5 × Upper Limit of Normal (ULN); Serum Creatinine ≤ 2.5 × ULN; Absolute Neutrophil Count (ANC) \\> 0.5 × 10⁹\u002FL; Platelet Count ≥ 30 × 10⁹\u002FL.\n4. Uncontrolled comorbidities, including but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina, arrhythmia, or psychiatric illness\u002Fsocial situations that would compromise compliance with the protocol.\n5. History of AML that was refractory to or did not achieve remission with prior treatment containing Venetoclax, Chidamide, or Azacitidine.\n6. History of hypersensitivity to any component of the study protocol.\n7. Pregnant women.\n8. Patients with active Central Nervous System (CNS) disease.\n9. Patients with Relapsed or Refractory (R\u002FR) AML.\n10. Patients who have undergone Hematopoietic Stem Cell Transplantation (HSCT).","ALL","18 Years","80 Years",{"count":21,"type":22},104,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study Objectives:\n\nTo evaluate the Relapse-Free Survival (RFS) and 1-year RFS rate in patients with Acute Myeloid Leukemia (AML) receiving maintenance therapy with Chidamide combined with Venetoclax and Azacitidine.\n\nStudy Design:\n\nProspective, Multicenter, Interventional Cohort Study.\n\nTotal Enrollment:\n\n104 subjects. Cohort 1 (MRD-Negative Patients): 61 subjects Chidamide (C): 5 mg, orally, once daily, Days 1-14. Azacitidine (A): 50 mg\u002Fm², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles. Cohort 2 (MRD-Persistent Positive Patients): 43 subjects Chidamide (C): 5 mg, orally, once daily, Days 1-28. Azacitidine (A): 50 mg\u002Fm², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles.",[28],"Acute Myeloid Leukemia (AML) in Remission",[30,31,32],"Acute Myeloid Leukemia (AML)","Chidamide","ABC","NOT_YET_RECRUITING","2026-04-02",{"date":36,"type":37},"2026-04-09","ACTUAL",{"date":39,"type":22},"2026-06-01",{"date":41,"type":22},"2029-06-01",{"name":43,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100438501","phase-1-phase-ibii-of-cpx-351-for-relapse-prevention-in-aml-100438501","NCT04990102","Phase IB\u002FII of CPX-351 for Relapse Prevention in AML","Phase IB\u002FII of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation","Inclusion Criteria:\n\n* Newly diagnosed patients \\> 18 years of age\n* Patients must be in CR or CRh (complete remission with partial count recovery).\n* Must have received ANY induction treatment with standard consolidation or hypomethylating agent (HMA) + venetoclax, for up to 6 cycles or no more than 12 cycles of treatment.\n* Must be able to start therapy within 3 months of last documented CR\n* De novo or secondary AML\u002Ftreatment related AML (non-M3) including AML with myelodysplasia-related changes (MRC), histologically confirmed\n* Patients must be ineligible for allogeneic BMT (for any reason including poor performance status, patient's preference, favorable AML not a candidate for transplant, or comorbidities and age precluding from transplant etc)\n* Cardiac ejection fraction ≥ 50% by transthoracic echocardiography or MUGA scan\n* Adequate hepatic and renal function defined as:\n\n  * Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN)\n  * Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3 is permissible if due to disease.\n  * Bilirubin ≤3 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)\n  * Estimated Creatinine Clearance ≥30 ml\u002Fmin (Cockcroft-Gault based on actual weight) (See Appendix A)\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3 (Appendix A)\n* Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.\n* Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices \\[IUDs\\], sexual abstinence, or sterilized partner) during the period of therapy and for at least 6 months after the last dose of study drug\n\nExclusion Criteria:\n\n* Prior allogeneic transplant\n* Previous cumulative anthracycline (doxorubicin equivalent) dose equal to or greater than 345 mg\u002Fm2, and for patients with prior mediastinal XRT, anthracycline dose equal to or greater than 295 mg\u002Fm2\n* Acute promyelocytic leukemia \\[t(15;17)\\]\n* If patient is unable to sign informed consent due to any serious medical condition, laboratory abnormality or psychiatric illness\n* Patients with evidence of uncontrolled current myocardial impairment (e.g. unstable ischemic heart disease, uncontrolled arrhythmia, symptomatic valvular dysfunction not controlled on medical therapy, uncontrolled hypertensive heart disease, and uncontrolled congestive heart failure)\n* History of Wilson's disease or other copper-related disorders\n* History of allergic reactions attributed to compounds of similar composition to cytarabine and daunorubicin or liposomal products\n* History of other malignancies, except:\n\n  * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated low risk prostate cancer or carcinoma in situ without evidence of disease.\n* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade ≤1, or to the levels dictated in the inclusion\u002Fexclusion criteria with the exception of alopecia.\n* Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia\n* Known active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).\n* Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, hepatitis C antibody, must have a negative polymerase chain reaction (PCR) result for the respective disease before enrollment. Those who are PCR positive will be excluded.\n* Any uncontrolled active systemic infection.\n* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.\n* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.\n* Known CNS involvement by leukemia\n* Erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome\n* Lactating or pregnant.\n* Unwilling or unable to participate in all required study evaluations and procedures.\n* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).\n* Currently active, clinically significant hepatic impairment (≥ moderate hepatic impairment according to the Child Pugh classification (class B or C))",{"count":54,"type":22},24,[56,57],"PHASE1","PHASE2","This is a phase IB\u002FII study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study.",[28],[61,62],"Acute Myeloid Leukemia","Remission","RECRUITING","2026-03-19",{"date":66,"type":37},"2026-03-23",{"date":68,"type":37},"2023-05-22",{"date":70,"type":22},"2026-12",{"name":72,"class":44},"Georgetown University",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":45},"100386629","phase-3-comparing-post-transplant-cyclophosphamide-as-gvhd-prophylaxis-to-standard-of-care-for-acute-leukemia-patients-100386629","NCT04314219","Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients","Comparing Post-Transplant Cyclophosphamide with Calcineurin Inhibitors As a GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling","PTCy-PMAT","Inclusion Criteria:\n\n* Patients with Acute Leukemias (AML, ALL) in morphologic complete remission with or without hematologic recovery\n* Patients must have a fully matched (8\u002F8) related donor willing to donate peripheral blood stem cells and must meet institutional criteria for donation\n* Planned Myeloablative conditioning regimen\n* Cardiac function: ejection fraction at rest ≥ 50% by MUGA or TTE\n* Estimated creatinine clearance greater than 50 mL\u002Fminute\n* Pulmonary function: DLCO ≥ 50% (adjusted for hemoglobin), and FVC and FEV1 ≥ 50%\n* Liver function: total bilirubin \\\u003C 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and ALT\u002FAST \\\u003C 2.5x the upper normal limit\n* Signed informed consent\n\nExclusion Criteria:\n\n* Karnofsky or Lansky Performance Score \\\u003C 70%.\n* Active disease\n* Patients with uncontrolled bacterial, viral, or fungal infections\n* Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated\n* Patients seropositive for HIV-1 or -2\n* Patients seropositive for HTLV-I or -II\n* Patients with active Hepatitis B or C viral replication by PCR\n* Women who are pregnant (positive serum or urine βHCG) or breastfeeding\n* Females with childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation\n* History of uncontrolled autoimmune disease or on active treatment\n* Patients with prior malignancies, except resected non-melanoma skin cancer or treated cervical carcinoma in situ; cancer treated with curative intent ≥ 5 years previously will be allowed; cancer treated with curative intent \\\u003C 5 years previously will not be allowed.","14 Years","65 Years",{"count":85,"type":22},264,[87],"PHASE3","This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate\u002Fcalcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.",[90,28],"Acute Lymphoblastic Leukemia (ALL) in Complete Remission",[92,93,94,95],"Sibling Donor Transplant","Allogeneic hematopoietic cell transplantation","GvHD Prophylaxis","Myeloablative regimen","2025-03-12",{"date":98,"type":37},"2025-03-13",{"date":100,"type":37},"2021-08-15",{"date":70,"type":22},{"name":103,"class":44},"King Faisal Specialist Hospital & Research Center",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100475950","phase-3-studying-conditioning-regimen-in-pediatric-transplantation---aml--script-aml-100475950","NCT05477589","Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","A Randomized, Multi-Center Phase III Trial Comparing Two Conditioning Regimens (CloFluBu and BuCyMel) in Children With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.","SCRIPT-AML","Inclusion criteria for randomization part of the study:\n\n* Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.\n* HCT is performed in a study participating center\n* All women of childbearing potential who have to have a negative pregnancy test within 2 weeks prior to the start of treatment.\n* Signed informed consent.\n* Any relapsed AML after initial treatment according to a defined international AML protocol. (NOPHO-DBH AML 2012\u002Fnew protocol), or AML in first remission with transplant indications and treatment according to national AML protocol (NOPHO-DBH AML 2012 or new protocol).\n* In hematological remission, defined as:\n\n\\\u003C 5 % leukemic blasts confirmed by flow cytometry (in patients with an informative leukemia associated immunophenotype) in a bone marrow sample taken ≤14 days prior to start of conditioning and no evidence of extramedullary disease, including in CNS and no leukemic blasts in the peripheral blood (verified by flow cytometry in case immature cells are detected in the peripheral blood differential).\n\n-Patients must have a related or unrelated donor fulfilling any of the following criteria: HLA 10\u002F10 allelic matched, identical, sibling BM donor or HLA 10\u002F10 or 9\u002F10 allelic matched related\u002Funrelated BM or PBSC donor orHLA 5-6\u002F6 unrelated or 6-7-8\u002F8 unrelated Cord Blood (UCB)\n\nInclusion criteria for observation\u002Fregistration only:\n\n* Diagnosis of acute myeloid leukemia\n* Indication for allogeneic stem cell transplantation, as defined by primary treatment protocol or treating physician.\n* Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.\n* Not eligible for randomization, either due to lack of consent or not fulfilling inclusion criteria for interventional part of the study.\n* Signed informed consent to prospectively register follow-up data.\n\nExclusion criteria for the randomization part of the study :\n\n* Diagnosis of myelodysplastic syndrome (MDS).\n* Diagnosis of juvenile myelomonocytic leukemia (JMML).\n* History of previous malignancy (AML diagnosed as secondary cancer).\n* Known diagnosis of Fanconi anemia.\n* Prior autologous or allogeneic hematopoietic stem cell transplant.\n* Planned prophylactic DLI or other immunotherapeutic interventions after HCT that are not included in the upfront protocol, Planned anti-leukemic medication after HCT that are not included in the upfront protocol\n* Known intolerance to any of the chemotherapeutic drugs in the protocol.\n* Major organ failure precluding administration of planned chemotherapy.\n* Patients with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.\n* Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion, e.g. malformation syndromes, cardiac malformations, metabolic disorders, renal impairment (\\\u003C30% of normal glomerular filtration rate), severe pulmonary, hepatic or cardiac impairment due to toxicity or infection.\n* Karnofsky \u002F Lansky score \\\u003C 50%\n* Females who are pregnant (positive serum or urine βHCG) or breastfeeding.\n* Females of childbearing potential or men who have sexual contact with females of childbearing potential unwilling to use effective forms of birth control or abstinence for one year after transplantation.\n* Subjects unwilling or unable to comply with the study procedures.\n\nExclusion criteria for the observational part of the study:\n\n* Diagnosis of Myelodysplastic syndrome (MDS).\n* Diagnosis of Juvenile myelomonocytic leukemia (JMML).\n* Age above 21 years at time of transplantation\n* No consent is given to prospectively register outcome data\n* Prior autologous or allogeneic hematopoietic stem cell transplant.",{"count":113,"type":22},170,[87],"It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)",[28,117],"Stem Cell Transplantation",[119,120,121,122,123],"Leukemia","Leukemia, Myeloid, Acute","Neoplasms","Haematopoietic cell transplantation","Paediatric","2024-12-16",{"date":126,"type":37},"2024-12-19",{"date":128,"type":37},"2022-06-07",{"date":130,"type":22},"2031-12-31",{"name":132,"class":133},"Vastra Gotaland Region","OTHER_GOV",17,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100470365","phase-2-aza--venetoclax-as-maintenance-therapy-in-younger-adults-with-aml-in-first-remission-100470365","NCT05404906","AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission","Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy","Inclusion Criteria:\n\n1. Diagnosis of favorable-risk acute myeloid leukemia (AML) according to revised 2017 European LeukemiaNet genetic risk stratification and are not immediate candidates for allogeneic stem cell transplant.\n2. Aged 18-64 years.\n3. Patients who have received remission induction therapy and 3-4 HiDAC or medium-dose cytarabine-based consolidation and are in their first remission.\n4. ECOG performance status of \\\u003C or = 3.\n5. Adequate organ function as follows:\n\n   1. Serum total bilirubin \\\u003C or = to 3 X the Upper Limit of Normal (ULN)\n   2. Aspartate Transaminase and alanine transaminase \\\u003C or = to 3 x ULN\n   3. Ccr（Creatinine Clearance Rate) \\> or ＝60 ml\u002Fmin\n   4. Left ventricular ejection fraction \\> or ＝50% determined by ultrasound.\n6. For females of childbearing age, they should have a negative serum or urine pregnancy test within 10 to 14 days of enrolling.\n7. For males of childbearing age, they should take effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.\n8. Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Acute promyeloid leukemia.\n2. Patients with active central nervous system (CNS) leukemia.\n3. Previously diagnosed with myelodysplastic syndrome (MDS) or myeloproliferative neoplasm(MPN) and progressed to AML.\n4. Patients with other progressive malignancies.\n5. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled and\u002For active systemic infection (viral, bacterial or fungal).\n6. Patients who have participated in other trials within 30 days before signing the informed consent.\n7. Females who are pregnant or lactating or intending to become pregnant during the study.","64 Years",{"count":144,"type":22},124,[57,87],"This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.",[28],"2022-08-18",{"date":150,"type":37},"2022-08-19",{"date":152,"type":37},"2022-06-25",{"date":154,"type":22},"2030-06",{"name":156,"class":44},"The First Affiliated Hospital of Soochow University",2]